Summary
McKesson Corporation reported third-quarter fiscal year 2017 revenues of $50.1 billion, a 5% increase year-over-year, driven by growth in its Distribution Solutions segment, particularly in North America. Despite revenue growth, gross profit saw a slight decrease of 2% due to weaker pharmaceutical pricing trends and a competitive market, though this was partially offset by acquisitions and LIFO inventory credits. Operating expenses increased by 1% due to acquisitions and ongoing restructuring costs, but also included a significant goodwill impairment charge of $290 million in the Technology Solutions segment. Net income attributable to McKesson Corporation for the quarter was $633 million, a slight decrease from $634 million in the prior year. Diluted earnings per share were $2.85, up from $2.73 in the prior year's comparable quarter. The company is actively managing its capital structure, with a notable increase in share repurchases authorized. Key strategic initiatives include the pending Healthcare Technology Net Asset Exchange with Change Healthcare, expected to close in the first half of calendar year 2017, and the recent acquisition of Rexall Health, further expanding its Canadian retail pharmacy presence. These strategic moves, coupled with ongoing operational adjustments and a focus on managing costs, indicate a dynamic period for McKesson.
Financial Highlights
52 data points| Revenue | $50.13B |
| Cost of Revenue | $47.32B |
| Gross Profit | $2.81B |
| Operating Expenses | $1.98B |
| Operating Income | $831.00M |
| Net Income | $633.00M |
| EPS (Basic) | $2.87 |
| EPS (Diluted) | $2.85 |
| Shares Outstanding (Basic) | 221.00M |
| Shares Outstanding (Diluted) | 222.00M |
Key Highlights
- 1Revenue increased by 5% to $50.1 billion for the quarter, primarily driven by the Distribution Solutions segment, boosted by acquisitions and market growth.
- 2Gross profit decreased by 2% to $2.8 billion, impacted by weaker pharmaceutical pricing, competitive pressures, and changes in manufacturer compensation, partially offset by acquisitions and LIFO credits.
- 3Operating expenses rose 1% to $1.98 billion, influenced by acquisitions and restructuring efforts, but also included a $290 million goodwill impairment charge in the Technology Solutions segment.
- 4Net income attributable to McKesson Corporation was $633 million, largely flat compared to the prior year's $634 million.
- 5Diluted earnings per share (EPS) for the quarter increased to $2.85 from $2.73 in the prior year, reflecting a slightly lower weighted average share count.
- 6The company completed the acquisition of Rexall Health for approximately $2.1 billion, expanding its Canadian pharmacy footprint.
- 7McKesson is progressing with the Healthcare Technology Net Asset Exchange with Change Healthcare, with closing expected in the first half of calendar year 2017.